Drug Trial Radar · NCT06423352
A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jun 5, 2024
Primary completion
Jul 17, 2025
Study completion Jul 17, 2025
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- May 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.
Conditions
- Mild to Moderate Hypertension
Interventions
ZilebesiranDrug
Zilebesiran administered by subcutaneous (SC) injection
PlaceboDrug
Placebo administered by SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Up to 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Fukuoka, Japan
Clinical Trial Site
Osaka, Japan
Clinical Trial Site
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.